ArticleJournal of neurology2026
High prevalence of treatable transthyretin cardiac amyloidosis in cardioembolic stroke: the first systematic cohort study.
Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWhile atrial fibrillation is the leading cause of cardioembolic stroke in elderly patients, the underlying cardiac substrate often remains unidentified. Transthyretin cardiac amyloidosis (ATTR-CA), a treatable cardiomyopathy affecting predominantly elderly males, causes atrial fibrillation and carries high thromboembolic risk but remains largely unrecognized among stroke physicians. With disease-modifying therapies now available, identifying ATTR-CA as a cause of cardioembolic stroke has become increasingly important.
methodsTo determine ATTR-CA prevalence and identify clinical indicators enabling systematic screening for this underdiagnosed cardiomyopathy, we performed a single-center retrospective cohort study of 143 consecutive patients with cardioembolic stroke among 430 ischemic stroke admissions. Patients with clinical suspicion underwent ⁹⁹ᵐTc-pyrophosphate scintigraphy for ATTR-CA diagnosis.
resultsATTR-CA was diagnosed in 14/143 patients (9.8%; 95% confidence interval: 5.4-16.0%). Notably, 50% of patients were newly diagnosed with ATTR-CA following stroke presentation. Compared with non-CA patients (n = 129), ATTR-CA patients demonstrated: male predominance (79% vs. 49%, p = 0.048), two-fold higher levels of troponin T (median 0.058 vs. 0.029 ng/mL, p = 0.035), characteristic biventricular hypertrophy, reduced left ventricular ejection fraction, and elevated E/e' ratio. Musculoskeletal manifestations, including spinal stenosis (57%), carpal tunnel syndrome (57%), and Popeye sign (75%), were highly prevalent.
conclusionsATTR-CA was found in nearly 10% of elderly patients with cardioembolic stroke, with half remaining undiagnosed until stroke presentation. Cardiac hypertrophy, elevated troponin levels, and musculoskeletal manifestations provide practical screening indicators for stroke physicians. Given the availability of disease-modifying therapies, these findings emphasize the importance of systematic ATTR-CA screening in cardioembolic stroke populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.